Δ9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism

Psychopharmacology

Volumn 126, Issue 2, 1996, Pages 125-131

  Lichtman, Aron H ^a   Martin, Billy R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

9 Tetrahydrocannabinol ( 9 THC); Cannabinoid antagonist; Physostigmine; Radial arm maze; Scopolamine; SR141716A; Working memory

Indexed keywords

CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CHOLINESTERASE INHIBITOR; DRONABINOL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHYSOSTIGMINE; RIMONABANT; SCOPOLAMINE;

ACCURACY; AMNESIA; ANIMAL EXPERIMENT; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; TASK PERFORMANCE; WORKING MEMORY;

ANIMALS; MALE; MAZE LEARNING; MEMORY; PHYSOSTIGMINE; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SCOPOLAMINE; TETRAHYDROCANNABINOL;

EID: 0030036308     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02246347     Document Type: Article

References (40)

1. Abel EL (1971) Retrieval of information after use of marihuana. Nature 231:58
2. 9-trans-tetrahydrocannabinol and a synthetic derivative on maze performance of rats. Pharmacology 4: 359-368
3. Collins DR, Pertwee RG, Davies SN (1995) Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-meidated blockade of long-term potentiation in the rat hippocampal slice. Br J Pharmacol 115: 869-870
4. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 263: 1118-1126
5. Compton DR, Johnson MR, Melvin LS, Martin BR (1992) Pharmacological profile of a series of bicyclic cannabinoid analogs - classification as cannabimimetic agents. J Pharmacol Exp Ther 260: 201-209
6. Compton DR, Rice KC, Costa BRd, Razdan RK, Melvin LS, Johnson MR, Martin BR (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265: 218-226
7. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exper Ther 277: 586-594
8. Crawley JN, Corwin RL, Robinson JK, Felder CC, Devane WA, Axelrod J (1993) Anandamide, and endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 46: 967-972
9. Dennes RP, Barnes JC (1993) Attenuation of scopolamine-induced spatial memory deficits in the rat by cholinomimetic and non-cholinomimetic drugs using a novel task in the 12-arm radial maze. Psychopharmacology 111: 435-141
10. Deutsch DG, Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46: 791-796
11. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949
12. Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38: 151-78
13. Evans EB, Wenger GR (1992) Effects of drugs of abuse on acquistion of behavioral chains in squirrel monkeys. Psychopharmacology 107: 55-60
14. 9-tetrahydrocannabinol in chimpanzees. Science 179: 490-492
15. Ferri S, Costa G, Murari G, Panico AM, Rapisarda E, Speroni E, Arrigo RR (1981) Investigations on behavioral effects of an extract of Cannabis sativa L. in the rat. Psychopharmacology 75: 144-147
16. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantative in vitro autoradiographic study. J Neurosci 11: 563-583
17. 9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 264: 294-307
18. 2 agonists with scopolamine on radial-arm maze peformance. Pharmacol Biochem Behav 38: 243-246
19. Lichtman AH, Dimen KR, Martin BR (1995) Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 119: 282-290
20. Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR (1988) Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 247: 1046-1051
21. Martin BR (1986) Cellular effects of cannabinoids. Pharmacol Rev 38: 45-74
22. Matsuoka N, Maeda N, Ohkubo Y, Yamaguchi I (1991) Differential effects of physostigmine and pilocarpine on the spatial memory deficits produced by two septo-hippocampal deafferentations in rats. Brain Res 559: 233-240
23. 9-THC) on mammalian salivary flow. J Pharmacol Exp Ther 206: 567-573
24. McGurk SR, Levin ED, Butcher LL (1991) Impairment of radialarm maze performance in rats following lesions involving the cholinergic medial pathway: reversal by arecoline and differential effecs of muscarinic and nicotinic antagonists. Neuroscience 44: 137-147
25. McGurk SR, Levin ED, Butcher LL (1992) Dopaminergic drugs reverse the impairment of radial-arm maze performance caused by lesions involving the cholinergic medial pathway. Neuroscience 50: 129-135
26. Murray CL, Fibiger BC (1985) Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine. Neuroscience 14: 1025-1032
27. 9-tetrahydrocannabinol (THC) on memory in the rat. Drug Alcohol Depend 28: 167-175
28. Olton DS (1987) The radial arm maze as a tool in behavioral pharmacology. Physiol Behav 40: 793-797
29. Paton WDM, Aboo Zar M (1968) The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips. J Physiol 194: 13-33
30. 9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 30: 67-71
31. 9-THC in the rat. Psychopharmacology 107: 117-124
32. Revuelta AV, Cheney DL, Costa E, Lander N, Mechoulam R (1980) Reduction of hippocampal acetylcholine turnover in rats treated with (-)-delta 8-tetrahydrocannabinol and its 1′,2′-dimethyl-heptyl homolog. Brain Res 195: 445-452
33. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244
34. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Alonso R, Congy C, Soubrié P, Brelière JC, Le Fur G (1995) Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56: 1941-1947
35. Tallarida RJ, Murray RB (1987) Manual of pharmacologic calculations with computer programs, 2nd edn. Springer, New York
36. Tilson HA, McLamb RL, Shaw S, Rogers BC, Pediatitakis P, Cook L (1988) Radial-arm maze deficits produced by colchicine administered into the area of the nucleus basalis are ameliorated by cholinergic agents. Brain Res 438: 83-94
37. Tripathi HL, Vocci FJ, Brase DA, Dewey WL (1987) Effects of cannabinoids on levels of acetylcholine and choline and on turnover rate of acetylcholine in various regions of the mouse brain. Alcohol Drug Res 7: 525-532
38. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63: 637-652
39. 9-THC in rats and rhesus monkeys. J Pharmacol Exp Ther 275: 1-6
40. Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR (1995b) Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34: 669-676